Cryoport, INC 8-K filings

Cryoport, Inc. held its 2026 Annual Meeting, confirming director elections, auditor ratification, and the approval of an amendment to its 2018 Omnibus Equity Incentive Plan.

Cryoport announced first quarter 2026 financial results, with total revenue up 16% year-over-year to $47.8 million, and raised its full-year revenue guidance.

Cryoport, Inc. announced strong financial results for Q4 and full-year 2025, surpassing revenue guidance and projecting continued growth for 2026.

Cryoport, Inc. reported a 15% year-over-year revenue increase to $44.2 million for Q3 2025 and raised its full-year 2025 revenue guidance to $170-$174 million.

Cryoport, Inc. reported strong second quarter 2025 financial results with a 14% year-over-year revenue increase and a significant capital infusion from the CRYOPDP divestiture and DHL partnership.

Cryoport, Inc. has completed the divestiture of its CRYOPDP business to DHL Group for approximately $200 million in cash and established a strategic partnership to enhance global life sciences supply chain solutions.

Cryoport, Inc. announced the successful outcome of its 2025 Annual Meeting of Stockholders, where all director nominees were elected, the independent auditor was ratified, and executive compensation and its annual frequency were approved.

Cryoport announces a 10% year-over-year increase in revenue for Q1 2025, reaching $41.0 million, fueled by strong growth in its Life Sciences Services segment and commercial Cell & Gene therapy support.

Cryoport divests its global specialty courier business, CRYOPDP, to DHL for approximately $138 million in cash plus repayment of intercompany loans, while also forming a strategic partnership to enhance supply chain solutions for the life sciences sector.

Cryoport's FY 2024 revenue reached $228.4 million, aligning with company guidance, while the company focuses on achieving positive adjusted EBITDA in 2025.

Cryoport's Q3 2024 results show a 9% increase in Life Sciences Services revenue, but a 14% decrease in Life Sciences Products revenue, with the company reaffirming its full-year revenue guidance.

Cryoport's second quarter results show strong growth in cell and gene therapy revenue, but overall revenue growth was modest and the company recorded a significant impairment loss.

Cryoport has authorized a $200 million repurchase program for its common stock and convertible notes, and will repurchase $160 million of its 2026 convertible senior notes at a discount.

Cryoport, Inc. successfully held its 2024 Annual Meeting of Stockholders, electing directors, ratifying the accounting firm, approving executive compensation, and amending the equity incentive plan.

Cryoport's first quarter 2024 results were below expectations, with a 13% year-over-year revenue decrease, though the company maintains its full-year revenue guidance.

Cryoport's 2023 financial results show a mixed performance with strong growth in services revenue offset by a decline in product revenue, and a significant goodwill impairment charge impacting overall profitability.

Cryoport has announced the transition of Edward Zecchini from the Board of Directors to a new executive role and has amended employment agreements for key executives.